Search clinical trials for: Placebo for BI 456906

Total 2777 results

Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Obesity | Overweight

China
Boehringer Ingelheim

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Taiwan, Netherlands, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE™-2)

Obesity | Diabetes Mellitus, Type 2

United States, Korea, Republic of, Australia, Spain, Belgium, China, Hungary, Canada, United Kingdom, Japan, Czechia, Poland, Greece, New Zealand, Denmark, Finland, Germany, Netherlands, Sweden
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (SYNCHRONIZE™-1)

Obesity

United States, Korea, Republic of, Belgium, Australia, China, Poland, Japan, Finland, Germany, Canada, Netherlands, New Zealand, Sweden, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Healthy | Obesity

Germany
Boehringer Ingelheim

Recruiting

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Obesity

United States, Korea, Republic of, Belgium, Australia, United Kingdom, Mexico, Spain, Germany, Taiwan, Netherlands, Brazil, Hungary, Denmark, Canada, Poland, Austria, China, Finland, Greece, Italy, Hong Kong, Czechia, Portugal, Saudi... and more
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Obesity

Belgium, Australia, Sweden, United States, Canada, Germany, Korea, Republic of, China, Netherlands, New Zealand, United Kingdom, Poland
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease (SYNCHRONIZE™JP)

Obesity

Japan
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

Healthy

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Obesity

Germany
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Australia, Canada, Germany, Spain, Taiwan, Hungary, Poland, Korea, Republic of, Austria, New Zealand, United Kingdom, Czechia, Puerto Rico
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim
Zealand Pharma

Completed

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

Liver Diseases | Healthy | Obesity

Germany, United States, Hungary, New Zealand, Slovakia, Poland
Boehringer Ingelheim

Completed

4 Weeks Treatment of Type II Diabetic Patients With BI 44847

Diabetes Mellitus, Type 2

Germany, Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Healthy | Renal Impairment

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Obesity | Overweight

Germany
AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Not yet recruiting

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Obesity
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Guang'anmen Hospital of China Academy of Chinese...
Hubei Hospital of Traditional Chinese Medicine; Hebei Yiling Hospital; The First... and other collaborators

Unknown

The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack (IRI-EXPLORE)

Myocardial Infarction

Korea, Republic of, Germany, Spain, Hungary, United Kingdom, Italy, Canada, Australia, Poland, Slovakia, New Zealand
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Switzerland, Netherlands, Portugal
Boehringer Ingelheim

Completed

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Active, not recruiting

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

Diabetic Nephropathies

Spain, Australia, United States, Canada, China, Japan, Malaysia, United Kingdom, Mexico, Portugal, Denmark, Hong Kong, Poland, New Zealand, Argentina, Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

Healthy

Japan
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

Healthy
Boehringer Ingelheim

Withdrawn

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

COVID-19
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim

Recruiting

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Bronchiectasis

United States, Korea, Republic of, Belgium, Germany, Australia, Spain, Italy, Netherlands, Denmark, Bulgaria, Japan, Turkey, Czechia, France, Hungary, Latvia, Poland, Canada, Portugal
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469

Healthy

Germany
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

Healthy
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

Psoriasis

United States, Canada, Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium

3

Subscribe